Davis Polk & Wardwell LLP advised the initial purchasers in connection with the Rule 144A/Regulation S offering by Genzyme Corporation of $1 billion aggregate principal amount of notes. The notes were offered in two $500 million tranches, one maturing in 2015 and the other in 2020.

Genzyme is a global biotechnology company dedicated to making a major impact on the lives of people with serious diseases. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing.

The Davis Polk corporate team included partner Alan Dean and associates Som Bhattacharyya and Scott Lunin. Partner William H. Weigel and associate Devasish Majumdar provided tax advice. Counsel Loyti Cheng and associate Ona Oshen provided environmental advice. Partner Steven S. Weiner of the Menlo Park office, associate David R. Bauer and summer associate Natalie A. Thomas provided intellectual property advice. Jack S. Keating was the legal assistant on the transaction. Unless otherwise noted, all members of the Davis Polk team are based in the New York office.